Duloxetine in the treatment of major depressive disorder: an open-label study

BACKGROUND: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants exhibiting dual reuptake inhibition of both serotonin (5-HT) and norepinephrine (NE) may achieve higher r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hudson, James I, Perahia, David G, Gilaberte, Inmaculada, Wang, Fujun, Watkin, John G, Detke, Michael J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2018694/
https://www.ncbi.nlm.nih.gov/pubmed/17725843
http://dx.doi.org/10.1186/1471-244X-7-43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2018694/
https://www.ncbi.nlm.nih.gov/pubmed/17725843
http://dx.doi.org/10.1186/1471-244X-7-43

Ejemplares similares